Matinas BioPharma (NYSEAMERICAN:MTNB) Announces Earnings Results

Matinas BioPharma (NYSEAMERICAN:MTNB) announced its quarterly earnings data on Wednesday. The company reported ($0.03) EPS for the quarter, Yahoo Finance reports.

Matinas BioPharma Price Performance

Shares of MTNB traded down $0.02 during trading hours on Friday, hitting $0.27. The company had a trading volume of 1,217,731 shares, compared to its average volume of 2,114,206. Matinas BioPharma has a 52-week low of $0.11 and a 52-week high of $0.89. The firm has a market cap of $58.88 million, a PE ratio of -2.26 and a beta of 1.52.

Institutional Investors Weigh In On Matinas BioPharma

Large investors have recently made changes to their positions in the company. Atria Wealth Solutions Inc. bought a new stake in shares of Matinas BioPharma during the 1st quarter valued at about $32,000. HRT Financial LP grew its stake in shares of Matinas BioPharma by 320.5% during the 4th quarter. HRT Financial LP now owns 54,567 shares of the company’s stock valued at $27,000 after purchasing an additional 41,590 shares during the period. Virtu Financial LLC bought a new stake in shares of Matinas BioPharma during the 2nd quarter valued at about $73,000. Balyasny Asset Management LLC bought a new position in shares of Matinas BioPharma during the 3rd quarter valued at approximately $63,000. Finally, Renaissance Technologies LLC grew its stake in shares of Matinas BioPharma by 258.3% during the 4th quarter. Renaissance Technologies LLC now owns 121,096 shares of the company’s stock valued at $61,000 after acquiring an additional 87,296 shares during the period. 11.77% of the stock is currently owned by institutional investors.

Matinas BioPharma Company Profile

Matinas BioPharma Holdings, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of various product candidates. It develops products using its lipid nanocrystal (LNC) platform technology. The company's LNC delivery technology platform utilizes lipid nano-crystals for the delivery of small molecules, nucleic acids, gene therapies, vaccines, proteins, and peptides.